Safety and efficacy of humanized anti‐CD19 CAR‐T (hCAR‐T) therapy in patients with B‐cell malignancies with HBV infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Mar 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Anti-CD19 chimeric antigen receptor T cells therapy-Shanghai Jibei biotechnology (Primary) ; Cyclophosphamide; Entecavir; Fludarabine; Tenofovir
Indications B-cell leukaemia; B-cell lymphoma; Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

19 Mar 2021 New trial record
01 Feb 2021 Results assessing safety and efficacy of utilizing humanized anti-CD19 chimeric antigen receptor-T cell therapy to treat relapsed refractory diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL) patients with HBV infection, published in the Hematological Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com